Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus | Zendy

Emiel F.�M. Wouters | Zendy; Dirk Bredenbröker | Zendy; Peter Teichmann | Zendy; Manja Brose | Zendy; Klaus F. Rabe | Zendy; Leonardo M. Fabbri | Zendy; Burkhard Göke | Zendy

Open Access

Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus

Author(s) -

Emiel F.�M. Wouters,

Dirk Bredenbröker,

Peter Teichmann,

Manja Brose,

Klaus F. Rabe,

Leonardo M. Fabbri,

Burkhard Göke

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2886

Subject(s) - roflumilast , medicine , glycated hemoglobin , gastroenterology , placebo , copd , endocrinology , glycemic , type 2 diabetes mellitus , diabetes mellitus , insulin , area under the curve , type 2 diabetes , pharmacology , alternative medicine , pathology

The phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of frequent exacerbations. In previous clinical studies, a transient and reversible weight decrease was reported with roflumilast, suggesting the systemic actions of this drug may impact metabolism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research